See more : Prime Number Acquisition I Corp. (PNACW) Income Statement Analysis – Financial Results
Complete financial analysis of Avadel Pharmaceuticals plc (AVDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avadel Pharmaceuticals plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Pato Chemical Industry Public Company Limited (PATO.BK) Income Statement Analysis – Financial Results
- Gladstone Acquisition Corporation (GLEE) Income Statement Analysis – Financial Results
- Emperor Metals Inc. (EMAUF) Income Statement Analysis – Financial Results
- Meituan (MPNGF) Income Statement Analysis – Financial Results
- Aimia Inc. (AIM.TO) Income Statement Analysis – Financial Results
Avadel Pharmaceuticals plc (AVDL)
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96M | 0.00 | 0.00 | 22.33M | 59.22M | 103.27M | 172.74M | 150.25M | 173.21M | 14.78M | 22.44M | 26.10M | 32.60M | 37.09M | 42.12M | 38.62M | 36.65M | 23.02M | 23.60M | 55.41M | 25.17M | 18.41M | 13.09M | 10.90M | 11.04M | 9.52M | 8.10M | 4.90M |
| Cost of Revenue | 846.00K | 1.49M | 815.00K | 5.74M | 12.13M | 17.52M | 16.30M | 13.25M | 10.92M | 3.38M | 4.35M | 5.86M | 6.28M | 6.91M | 10.12M | 9.62M | 17.32M | 6.25M | 2.53M | 3.60M | 3.68M | 2.37M | 2.17M | 1.75M | 2.09M | 3.53M | 3.10M | 400.00K |
| Gross Profit | 27.12M | -1.49M | -815.00K | 16.59M | 47.09M | 85.75M | 156.44M | 137.00M | 162.29M | 11.39M | 18.09M | 20.24M | 26.32M | 30.18M | 32.00M | 29.00M | 19.33M | 16.77M | 21.07M | 51.81M | 21.49M | 16.03M | 10.92M | 9.15M | 8.95M | 5.99M | 5.00M | 4.50M |
| Gross Profit Ratio | 96.97% | 0.00% | 0.00% | 74.29% | 79.52% | 83.04% | 90.56% | 91.18% | 93.69% | 77.10% | 80.62% | 77.55% | 80.72% | 81.36% | 75.98% | 75.09% | 52.75% | 72.85% | 89.30% | 93.50% | 85.39% | 87.11% | 83.45% | 83.95% | 81.10% | 62.90% | 61.73% | 91.84% |
| Research & Development | 13.26M | 20.70M | 17.10M | 20.44M | 32.92M | 39.33M | 34.22M | 34.61M | 25.61M | 17.30M | 26.69M | 26.12M | 25.09M | 28.69M | 30.42M | 36.25M | 43.56M | 38.23M | 47.30M | 35.36M | 20.22M | 12.24M | 10.66M | 9.79M | 11.05M | 10.61M | 10.10M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 151.71M | 74.52M | 68.50M | 32.41M | 30.18M | 100.36M | 58.86M | 44.18M | 21.71M | 15.70M | 13.31M | 14.15M | 10.81M | 11.33M | 13.34M | 12.91M | 16.63M | 17.38M | 14.54M | 7.61M | 5.97M | 4.02M | 3.41M | 3.46M | 3.69M | 3.63M | 3.20M | 12.60M |
| Other Expenses | 0.00 | 3.35M | 217.00K | 406.00K | 816.00K | 1.90M | 2.09M | -6.55M | 0.00 | -36.00K | 573.00K | 102.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 164.97M | 95.22M | 85.60M | 53.25M | 63.92M | 146.31M | 96.74M | 92.68M | 59.88M | 44.75M | 39.99M | 40.27M | 35.90M | 40.02M | 43.75M | 49.16M | 60.18M | 55.61M | 61.84M | 42.97M | 26.19M | 16.26M | 14.08M | 25.26M | 15.95M | 15.28M | 14.00M | 13.50M |
| Cost & Expenses | 165.81M | 95.22M | 85.60M | 59.00M | 76.04M | 163.82M | 113.04M | 105.93M | 70.81M | 48.13M | 44.34M | 46.13M | 42.18M | 46.93M | 53.87M | 58.78M | 77.50M | 61.86M | 64.37M | 46.58M | 29.87M | 18.63M | 16.24M | 27.01M | 18.04M | 18.81M | 17.10M | 13.90M |
| Interest Income | 0.00 | 11.12M | 2.13M | 12.59M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 963.00K | 254.00K | 629.00K | 667.00K | 464.00K | 525.00K | 1.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.89M | 12.34M | 9.94M | 12.99M | 12.48M | 10.62M | 1.05M | 963.00K | 6.30M | 9.27M | 4.35M | 118.00K | 73.00K | 24.00K | 100.00K | 18.00K | 16.00K | 35.00K | 68.00K | 45.00K | 29.00K | 49.00K | 52.00K | 51.00K | 0.00 | 95.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.77M | 1.49M | 815.00K | 1.69M | 2.49M | 7.43M | 4.88M | 14.49M | 13.13M | 14.14M | 3.06M | 3.18M | 3.35M | 4.70M | 5.92M | 7.25M | 6.20M | 5.64M | 4.74M | 2.53M | 1.71M | 1.46M | 1.27M | 1.11M | 1.21M | 1.04M | 700.00K | 900.00K |
| EBITDA | -149.13M | -97.60M | -84.78M | -34.97M | -23.61M | -95.15M | 65.89M | 5.73M | 115.54M | -94.74M | -50.03M | -8.36M | -5.16M | -4.05M | -5.42M | -11.30M | -33.22M | -33.20M | -36.03M | 9.34M | -2.99M | 1.24M | -1.89M | -14.99M | -5.79M | -8.25M | -8.30M | -8.10M |
| EBITDA Ratio | -533.29% | 0.00% | 0.00% | -141.52% | -24.22% | -51.44% | 37.39% | 39.14% | 66.70% | -123.76% | -95.02% | -139.41% | -30.64% | -28.24% | -27.64% | -29.72% | -93.83% | -142.19% | -175.99% | 20.77% | -12.30% | -6.47% | -14.82% | -137.98% | -53.73% | -85.84% | -111.11% | -179.59% |
| Operating Income | -137.85M | -98.56M | -85.55M | -36.66M | -16.83M | -104.93M | 88.30M | -4.97M | 71.45M | -93.86M | -50.03M | -3.49M | -9.58M | -9.84M | -11.75M | -20.16M | -40.85M | -38.84M | -40.77M | 8.84M | -4.70M | -223.00K | -3.16M | -16.11M | -7.00M | -9.29M | -9.00M | -9.00M |
| Operating Income Ratio | -492.97% | 0.00% | 0.00% | -164.15% | -28.42% | -101.60% | 51.12% | -3.30% | 41.25% | -635.24% | -222.93% | -13.36% | -29.40% | -26.53% | -27.90% | -52.20% | -111.44% | -168.71% | -172.76% | 15.94% | -18.67% | -1.21% | -24.11% | -147.74% | -63.41% | -97.57% | -111.11% | -183.67% |
| Total Other Income/Expenses | -22.93M | -12.88M | -7.60M | -10.90M | -14.47M | -8.27M | 3.16M | -4.75M | 6.26M | 3.33M | -4.06M | 1.98M | 1.00M | 1.07M | 314.00K | 1.60M | 1.42M | 1.52M | 9.11M | 463.00K | 272.00K | 2.68M | 295.00K | 11.27M | 322.00K | 232.00K | 800.00K | 600.00K |
| Income Before Tax | -160.78M | -111.44M | -93.15M | -5.08M | -38.58M | -113.20M | 91.47M | -9.72M | 78.39M | -90.33M | -54.10M | -7.93M | -8.58M | -8.77M | -11.44M | -18.56M | -39.43M | -37.32M | -31.66M | 9.30M | -4.00M | 2.45M | -2.86M | -4.83M | -6.68M | -9.06M | -8.20M | -8.40M |
| Income Before Tax Ratio | -574.96% | 0.00% | 0.00% | -22.75% | -65.16% | -109.61% | 52.95% | -6.47% | 45.26% | -611.38% | -241.03% | -30.38% | -26.33% | -23.63% | -27.16% | -48.06% | -107.58% | -162.12% | -134.18% | 16.78% | -15.88% | 13.32% | -21.85% | -44.34% | -60.49% | -95.14% | -101.23% | -171.43% |
| Income Tax Expense | -501.00K | 26.03M | -15.82M | -12.11M | -5.36M | -17.89M | 24.22M | 31.56M | 37.74M | -1.41M | -11.17M | -4.70M | 192.00K | 209.00K | -6.23M | -6.48M | -1.69M | -2.12M | -4.29M | -3.20M | -503.00K | -553.00K | 14.00K | 50.00K | 16.00K | -1.25M | -1.40M | -1.50M |
| Net Income | -160.28M | -137.46M | -77.33M | 7.03M | -33.23M | -95.30M | 67.25M | -41.28M | 40.66M | -84.91M | -42.93M | -3.23M | -8.77M | -8.98M | -11.44M | -12.08M | -37.74M | -35.20M | -27.38M | 12.50M | -3.49M | 3.01M | -2.87M | -9.46M | -6.69M | -7.81M | -6.80M | -6.90M |
| Net Income Ratio | -573.17% | 0.00% | 0.00% | 31.47% | -56.11% | -92.29% | 38.93% | -27.47% | 23.47% | -574.66% | -191.26% | -12.37% | -26.91% | -24.20% | -27.16% | -31.29% | -102.95% | -152.91% | -116.01% | 22.56% | -13.88% | 16.33% | -21.96% | -86.78% | -60.63% | -82.04% | -83.95% | -140.82% |
| EPS | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.66 | -1.00 | 1.00 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.58 | -0.20 | 0.19 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| EPS Diluted | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | -2.55 | 1.61 | -1.00 | 0.93 | -2.34 | -1.69 | -0.13 | -0.36 | -0.37 | -0.47 | -0.50 | -1.57 | -1.48 | -1.19 | 0.53 | -0.20 | 0.18 | -0.18 | -0.62 | -0.52 | -0.65 | -0.65 | -0.80 |
| Weighted Avg Shares Out | 80.17M | 60.09M | 58.54M | 53.00M | 37.40M | 37.33M | 40.47M | 41.25M | 40.58M | 36.21M | 25.41M | 24.95M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 21.51M | 17.76M | 16.20M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
| Weighted Avg Shares Out (Dil) | 80.17M | 60.09M | 58.54M | 54.94M | 37.40M | 37.33M | 41.77M | 41.25M | 43.62M | 36.21M | 25.45M | 25.09M | 24.67M | 24.41M | 24.23M | 24.08M | 24.02M | 23.81M | 23.00M | 23.56M | 17.76M | 16.71M | 16.20M | 15.33M | 12.94M | 12.05M | 10.46M | 8.63M |
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to...
Avadel Pharmaceuticals to Present at the Jefferies Healthcare Conference
DUBLIN, Ireland, June 01, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Healthcare Conference...
Why Shares of Avadel Soared This Week
Avadel said it plans to launch its lead therapy to treat excessive daytime sleepiness in adults with narcolepsy, in early June. The company had no revenue in the first quarter.
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz Launch
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference
DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham...
Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior Vice President-Medical and Clinical Affairs Richard...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on...
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For Lumryz
Avadel Pharmaceuticals' Lumryz has the potential to transform the narcolepsy treatment market. Avadel estimates that the total potential patient population for Lumryz could be greater than 30,000, with a market opportunity of over $3.0 billion annually.
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global...
Avadel: Lumryz Overhang Now Removed, Rate Buy
Lumyrz overhang now removed with competitor ordered to delist patent from FDA's Orange Book. The treatment has potential to create a remedial breakthrough in narcolepsy.
Source: https://incomestatements.info
Category: Stock Reports